Revvity In-Depth Value Investment Research

Industry Structure and Moat

Revvity operates in a hybrid industry of life sciences tools + in vitro diagnostics/specialty diagnostics. Over the long term, this industry usually does not decline, because drug R&D, molecular and cell research, newborn screening, autoimmune testing, reproductive health, and clinical laboratory automation all have sustained demand. Over the near-to-medium term, however, it is often affected by academic and government funding, hospital budgets, diagnostics policy, tariffs, and regional price regulation. In its risk factors, the company itself explicitly says that recent U.S. funding and regulatory changes have made customers more cautious about purchases of both instruments and consumables. Fact + inference: this is not a sunset industry, but it is also not an ideal industry that is completely insulated from macro disruption. It is more like a long-term upward, periodically volatile specialized track. I rate industry attractiveness at 3/5.

From a competitive structure perspective, Revvity's biggest problem is not that it has "no position," but that its position is "fairly strong, yet not overwhelming." At Investor Day, the company positioned itself as a distinctive platform spanning from pre-clinical discovery to clinical outcomes, emphasizing that after M&A and divestitures, it has entered faster-growing segments with higher-quality margins. In 2025, the company's Life Sciences and Diagnostics segments each contributed nearly half of revenue. On the 2025 new-structure basis, Life Sciences revenue was $1.431 billion and Diagnostics revenue was $1.425 billion. But compared with industry leaders, its scale remains much smaller. Thermo Fisher's 2025 revenue was $44.56 billion, Danaher's 2025 revenue was $24.57 billion, Agilent's 2025 revenue was $6.95 billion, while Revvity had only $2.86 billion. The inference is that Revvity is a niche leader, not a platform king.

The moat becomes clearer when broken down.

Brand advantage: medium. Revvity's corporate brand itself is not as overwhelming as Roche or Thermo Fisher, but it owns a series of technologies and product brands that are recognizable in niche use cases, such as BioLegend, EUROIMMUN, and the Signals software family. In particular, brand awareness is not zero in antibodies, immunology reagents, autoimmune testing, and newborn screening workflows. Investor Day also disclosed that its Life Sciences Solutions introduces more than 1,500 internally developed antibodies, kits, and reagents each year. This shows it is not a pure distributor, and it does have sustained product development capability.

Cost and scale advantage: limited. Revvity certainly has global scale, but compared with platform giants such as Thermo Fisher and Danaher, it does not have enough scale to create industry-wide advantages in procurement, manufacturing, and sales networks. What it can do is build reasonable scale within local categories, such as immunology reagents, specific diagnostics workflows, and research software. The company itself also acknowledges that many competitors have stronger resources, intellectual property, manufacturing capabilities, and distribution channels.

Network effects: weak. Pure network effects are weak. But in software and data workflows, there is some "pseudo-network effect/process lock-in": once customers move analysis, experimental design, data management, and compliance workflows into the software, migration creates friction.

Switching costs: medium to high. This is one of Revvity's most important moats. Once a clinical or research workflow is built around a reagent, an analytical platform, a validated assay, or a laboratory informatics system, customers do not switch easily. The company's disclosure about placed instruments and related reagent revenue is typical evidence. Deferred revenue mainly comes from SaaS, maintenance, and prepaid storage, which also supports this point.

Regulatory, patent, and process barriers: present, but not ironclad. Diagnostics products are subject to FDA and international regulatory constraints, and IP protection is also important. But the company also clearly notes that third parties may challenge its patents or design around its applications, while regulatory changes may affect demand. In other words, barriers exist, but they can be eroded.

Data, culture, operations, and capital allocation: partly advantageous, but not yet proven strong enough. At its 2024 Investor Day, the company emphasized AI, software, and workflow integration, as well as disciplined capital allocation. Its proxy statement shows a relatively standard governance structure. The issue is that there was still sizable restructuring in 2025, and Q1 2026 continued to involve layoffs and integration. This shows the organization is still in a "refinement period," not yet at the stage of "compounding on autopilot."

Overall, I rate Revvity's moat strength at 3/5. Its moat is more like "many medium moats stacked together". These include workflow validation, consumables lock-in, software stickiness, niche brands, and regulatory requirements, rather than one extremely wide river. My judgment is that the moat is currently broadly stable, but it is not obviously widening. If competitors want to replicate the whole portfolio, it would take years and substantial capital. But replicating a specific local component may not be especially difficult.

Management and Capital Allocation

At the management level, Revvity gives me the impression of standard governance, relatively candid communication, and somewhat rational capital allocation, but still short of "textbook capital allocation master." The proxy statement shows that the CEO's share ownership requirement is 5 times base annual salary, and other executives also have clear ownership requirements. As of February 17, 2026, all named executive officers and directors complied with the ownership guidelines. CEO Prahlad Singh beneficially owned about 416,376 shares, and all executive officers and directors together owned about 945,995 shares, in each case less than 1%. This means management has economic alignment, but it is not a founder-led, very high ownership model.

On governance systems, the company has several positive signals: clawback provisions, prohibitions on hedging and pledging, requirements for executives to trade under 10b5-1 plans, and proxy access for shareholders. For a large-cap U.S. company, these are not surprises, but they fall into the category of "should exist and do exist." Such arrangements cannot guarantee excellent capital allocation, but they can reduce obvious governance risk.

The most commendable capital allocation move was completing the sale of the Applied, Food and Enterprise Services business in 2023, further focusing on diagnostics and life sciences. The 2025 annual report defines this as an important part of portfolio reshaping, and Investor Day further describes the company as having moved into a faster-growing business mix with higher-quality margins. At minimum, this action shows management is not blindly pursuing scale, and is genuinely adjusting business boundaries. In early 2026, the company also completed a small software acquisition of ACD/Labs for $72 million plus up to $8 million in contingent consideration. Compared with large "bet-the-company acquisitions," this size is restrained.

On buybacks, the company spent about $821 million repurchasing shares in 2025, reducing year-end shares outstanding from 120.646 million to 112.281 million. The annual report also disclosed that in early 2026 it continued to repurchase about 609,000 shares for $64.2 million. Based on about 8.51 million shares and about $816 million under the old and new 2025 repurchase plans combined, the average repurchase price was roughly around $96, somewhat below the recent price of about $101. This shows the 2025 buybacks were not reckless. But from the perspective of "intrinsic value growth per share," I still need to reserve judgment: if my conservative intrinsic value estimate is right, $96 may not be a clearly undervalued zone. In other words, this was reasonable buyback activity, not legendary buyback activity.

My biggest reservation about management is not honesty, but whether historical M&A capital has truly created high enough returns. After all, as of Q1 2026, the company carried $6.61 billion of goodwill and $2.31 billion of net intangible assets on the balance sheet, together accounting for the vast majority of total assets. Meanwhile, GAAP ROE, ROA, and my estimate of ROIC based on total capital are all unimpressive. In other words, management has built a better business mix through acquisitions, but from the perspective of "how much real return each dollar of shareholder capital has generated," the report card is still not pretty.

In addition, one often overlooked fact needs emphasis: Revvity's adjusted metrics like to exclude amortization, restructuring, transformation, litigation, and other items, but 2025 restructuring expenses were $55.93 million, involving about 5% of employees; Q1 2026 had another $10.68 million of restructuring expenses, affecting about 2% of employees. This shows some "non-recurring" items are not quite so occasional. For long-term owners, this weakens confidence in non-GAAP metrics. Based on the above, I rate management and capital allocation at 3/5: trustworthy, but not exceptional.

Financial Quality and Owner Earnings

If we look only at "accounting profit," Revvity may appear average. If we look at "cash flow," it looks better. But once we add in the "large intangible assets created by acquisitions" and "overall returns on capital," it falls back from "pretty good" to "upper-middle." That is the truest picture of this company's financial quality.

Start with growth. From 2023 to 2025, revenue increased from $2.751 billion to $2.856 billion, a cumulative increase of only about 3.8% over two years. Q1 2026 revenue was $711 million, up from $665 million year over year, indicating some improvement on the revenue side. The problem is that growth is not fast, and margin improvement is not yet solid. Gross margin declined in both 2025 and Q1 2026, which means the market's current label of "high-quality mid-speed growth" still needs more actual operating results to be validated.

Next, cash flow. Operating cash flow from continuing operations in 2024 and 2025 was $665 million and $589 million, respectively, well above net income from continuing operations of $283 million and $240 million. Corresponding free cash flow was also about $578 million and $515 million. This shows earnings are not "paper profits". In fact, GAAP profit is depressed by amortization and other non-cash expenses. But there are two important qualifications here. First, this high cash conversion partly comes from amortization of large intangible assets created by acquisitions. Second, accounts receivable increased by $101 million in 2025, a clear drag on operating cash flow that year. The company explained it as a China collection timing issue, and accounts receivable then fell back to $691 million in Q1 2026, indicating at least part of the receivables pressure was a timing factor.

The balance sheet is not dangerous, but it is certainly not "fortress-like." As of Q1 2026, cash was about $860 million, total debt was about $3.208 billion, and net debt was about $2.348 billion. Based on 2025 operating income from continuing operations of $357 million and depreciation and amortization of $405 million, net debt/EBITDA was about 3.1x. Based on 2025 operating income and interest expense of $92.19 million, EBIT/interest coverage was about 3.9x. This is still manageable, but it is no longer a capital structure where "anything goes." For a conservative investor, this means the company can withstand pressure through cash flow, but the next large acquisition should not be too aggressive.

The most important warning sign is return on capital. If roughly calculated using GAAP net income from continuing operations and average shareholders' equity, 2025 ROE was only around 3%. ROA was about 2%. If after-tax operating profit is divided by rough invested capital, defined as "shareholders' equity + debt - cash," 2025 ROIC was also only low single digits. I must emphasize: this is the "owner's perspective" result including goodwill and acquisition capital. Many sell-side analysts or management teams use "adjusted operating profit" to tell the story, but as a long-term business owner, I care more about what real returns were earned on the actual cash paid for these assets. From this angle, Revvity's financial quality is "decent cash flow, but ordinary returns on capital."

Next, use "owner earnings" to assess true earning power. My conservative method uses the following basis: start with 2025 net income from continuing operations of $239.9 million, add back depreciation and amortization of $405.3 million and stock-based compensation of $22.8 million, subtract total capital expenditures of $73.5 million, and then subtract about $96.8 million of working capital consumption in 2025. This produces conservative owner earnings of about $493 million. This method is intentionally conservative: I do not add back any portion of total capex that may be growth capex, and I do not ignore the real shareholder cost of stock-based compensation. At a recent share price of about $101.22, the current equity value corresponds to roughly 23x owner earnings. On an enterprise value basis, it is close to 28x. For a company with some quality, but not a super moat, this is not cheap.

My financial conclusion is: there are no obvious signs of financial fraud or major accounting distortion, and no material weaknesses in the control environment were observed; but adjusted earnings need to be discounted, and the key issue is the tension between cash flow and returns on capital. This company is not a "bad financial student," but it is far from a "top financial student."

Valuation and Margin of Safety

The recent market price is the most important variable in this case. Based on public market quotes in late May, RVTY recently closed at $101.22. Using about 111.629 million shares outstanding at the end of Q1 2026, equity market capitalization was about $11.3 billion. After subtracting about $860 million of cash and adding about $3.208 billion of total debt, enterprise value was about $13.6 billion. This means the market is not valuing it as a "mediocre tools company," but as a company with "decent cash flow quality and margins that will eventually recover."

Owner-Earnings Discounted Valuation

To get as close as possible to a "business owner" perspective, I use 2025 conservative owner earnings of $490 million and set three scenarios. All valuations here target equity value/per-share value, with net debt already deducted from enterprise value. It must be emphasized: this is not precise science. It is a way to test whether today's price is overly optimistic using a clear set of assumptions.

View: RVTY's current price is close to reasonable only under the optimistic scenario. Under the base and conservative scenarios, it is clearly expensive. In other words, buying it today essentially prepays for several good things to happen at the same time: successful portfolio optimization, higher software/service mix, margin recovery, and improvement in the academic and diagnostics environment. For conservative investors, that is not a margin of safety.

Relative Valuation

First, look at Revvity's own static valuation. Based on a recent equity market capitalization of about $11.3 billion, 2025 P/S is about 4.0x. Based on 2025 free cash flow from continuing operations of about $515 million, P/FCF is about 22x. Based on conservative owner earnings of $493 million, P/OE is about 23x. Based on Q1 2026 shareholders' equity of about $7.183 billion, P/B is about 1.6x. Based on rough 2025 EBITDA, EV/EBITDA is about 18x. Put together, these metrics give me the impression that it is not absurdly expensive, but it is definitely not cheap. If you only look at P/B, you may think it is "not high." But for acquisition-heavy companies like this, P/B has limited reference value because book equity is mainly backed by goodwill and intangible assets, not hard assets that can be quickly liquidated.

Compared with peers, Revvity is not the most expensive, but it is also not meaningfully cheap. Agilent's 2025 revenue was $6.948 billion, operating cash flow was $1.559 billion, capital expenditures were $407 million, free cash flow was about $1.152 billion, and book equity was $6.741 billion. Based on a late-May share price of about $135.38 and 283 million shares outstanding, Agilent's current valuation is roughly P/S about 5.5x, P/FCF about 33x, and P/B about 5.7x. Thermo Fisher's 2025 revenue was $44.56 billion and free cash flow was $6.337 billion. Danaher's 2025 revenue was $24.57 billion and free cash flow was $5.293 billion. Their scale, platform value, and operating systems are all clearly stronger than Revvity's. The inference is that RVTY trades below some high-quality peers because it deserves a discount, but the current discount is still not large enough for me to ignore its weaker overall returns on capital.

Another useful comparison is to examine the metric by which the market is willing to value it. Reuters reported that the company's full-year non-GAAP/adjusted EPS guidance issued in early 2026 was about $5.35 to $5.45. At a recent share price of about $101, the market is valuing it at roughly 18.6x to 18.9x forward adjusted PE. This multiple is not unreasonable by itself, but the problem is that adjusted EPS is not owner earnings, nor is it the real return rate after including acquisition capital costs. For a company with a heavy M&A history, looking only at adjusted PE can easily overstate how "cheap" it is.

Asset and Liquidation Value

If we assess Revvity through an "asset floor" lens, the conclusion is unfavorable. In Q1 2026, the company had book shareholders' equity of about $7.183 billion, but goodwill was $6.611 billion and net intangible assets were $2.307 billion. In other words, if goodwill and intangible assets are simply deducted, tangible net assets are negative. Of course, this does not mean the company has no value. These intangible assets, brands, customer relationships, and technology platforms are part of real operating value. But for conservative investors, it at least shows that RVTY does not have a strong "liquidation protection cushion." Its value mainly comes from future cash flow, not hard assets on the balance sheet.

Margin of Safety Judgment

My margin of safety judgment is clear: the current margin of safety is insufficient.

The three most fragile valuation assumptions are as follows. First, the market assumes Revvity's margins will steadily recover, but the gross margin trends in 2025 and Q1 2026 have not yet confirmed that. Second, the market assumes its 80% recurring revenue can naturally translate into higher-quality, higher-return growth, but this still needs to be proven from the perspective of total returns on capital. Third, the market assumes M&A integration has entered the "harvest period", yet the actual result is that the company continues to incur restructuring, transformation, and "non-recurring" adjustments. If any one of these three premises breaks, the annualized return from the current price will be ordinary.

Therefore, my price ranges are as follows. Ideal buy price:$50 to $65. This corresponds to applying a 20% to 30% discount to the base value. Acceptable holding price:$65 to $85. This range remains acceptable for existing holders, but it is not enough for me to make a large new purchase. Clearly overvalued zone:above $95. This level is already close to, or even above, the low end of my optimistic intrinsic value. Under this framework, the current price of about $101 is closer to "good company, bad price" than to "cheap good company."

Risks, Comparisons, Checklist, and Final Judgment

The most important risk is not share price volatility, but permanent capital loss. My ranking is as follows. First is competition and technology substitution risk: the company itself explicitly says many competitors have stronger resources, IP, manufacturing, and distribution capabilities. If product iteration falls short of expectations, customers can gradually shift. Second is policy and regulatory risk: the diagnostics business is subject to FDA and international regulations, while government funding and hospital/public laboratory budgets are unstable. Third is financial leverage and M&A risk: net debt is not extreme, but the large goodwill left by a heavy acquisition history means that if growth and margin recovery fall short, impairments or low returns could weigh on per-share intrinsic value for a long time. Fourth is supply chain and tariff risk: 2025 and Q1 2026 gross margins have already been affected by tariffs. Fifth is China and academic market demand risk: 2025 cash flow was explicitly affected by China collection timing, and the company has repeatedly noted uncertainty in the research funding environment.

The strongest bear case is actually simple: Revvity may be an acquisition-built portfolio company that "looks stable, but actually does not generate high returns." Multiple brands, products, software offerings, and testing platforms make the story feel complete. But if you start from "returns on capital rather than product story," you find that the capital shareholders put in has not generated especially impressive returns. The current price also requires the market to keep believing in "margin recovery, growth recovery, fewer adjustments, and acquisitions beginning to bear fruit." If these only come through halfway, the 10-year return is likely to be only low-to-mid single digits. I believe this bear case is valid.

What facts would overturn my analysis and make me admit I was wrong? If the following facts appear over the next two to three years, I would become more positive: first, gross margin recovers to above 56% to 57% and GAAP operating margin rises steadily; second, owner earnings can sustain mid-to-high single-digit growth without relying on large acquisitions; third, net debt/EBITDA falls to around 2x while R&D and buybacks are still maintained. Conversely, if the following occur, I would become more conservative or even reject the investment thesis: first, restructuring and "non-recurring" expenses repeat year after year; second, demand recovery falls short and revenue remains stuck in low single-digit growth for a long period; third, new acquisitions continue to increase goodwill while returns on capital decline instead of rising.

Compared with other opportunities, Revvity does not currently stand out. Compared with the strongest industry benchmarks, Thermo Fisher and Danaher are stronger in scale, platformization, operating system, and cash flow size. Compared with closer peers such as Agilent, Agilent also has stronger platform characteristics, service mix, and capital market recognition. Compared with the risk-free rate, the U.S. 10-year Treasury yield in late May was roughly in the 4.3% to 4.6% range, while my estimate of Revvity's base-case annualized return at the current price is only 4% to 6%, providing no obvious risk compensation. Compared with broad market indexes, RVTY currently also does not offer a clear enough discount to make me think it is definitely more attractive than buying a high-quality broad-based asset. In other words: it deserves a place on the watchlist, but it does not yet deserve priority use of your capital.

Below is a compressed investment checklist.

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Revvity is a life sciences and diagnostics platform with an understandable business, acceptable cash flow, and a decent niche position, but at the current price you are paying more of a "good company price" than a "conservative investor price."

【Core Bull Points】 First, the business structure is more focused than the old PerkinElmer. After the sale of non-core businesses in 2023, the portfolio has better recurring revenue, brand quality, and end-market quality. Second, software, services, consumables, and reagents bring relatively high revenue stickiness. Management puts recurring revenue at about 80%, and deferred revenue is also growing. Third, operating cash flow and free cash flow were decent in 2024 to 2025, with cash earnings significantly above GAAP net income. Fourth, the large 2025 buyback mostly occurred below the current price, and governance systems are relatively standard. Fifth, Q1 2026 revenue returned to year-over-year growth, showing that the demand environment is not deteriorating.

【Core Bear Points】 First, overall returns on capital are not high, and GAAP ROE/ROIC under an acquisition-heavy balance sheet are not excellent. Second, the moat is a "stacking of multiple medium advantages," still some distance from top-tier platform leaders. Third, gross margin was under pressure in 2025 and Q1 2026, while the current price already requires margin recovery. Fourth, goodwill and intangible assets account for an extremely high proportion of assets, leaving little hard-asset protection. Fifth, restructuring, transformation, litigation, and other "adjustments" continue to occur, so non-GAAP metrics need to be discounted.

【Key Assumptions】 The investment thesis requires three conditions: first, owner earnings maintain at least mid-single-digit growth; second, gross margin and GAAP operating margin recover in the coming years; third, management stops diluting returns on capital through large, high-priced acquisitions.

【Fair Buy Price】 $50 to $65. This is based on my conservative and base intrinsic value range, with at least a 20% to 30% margin of safety required. Below $60, I would become meaningfully more interested. Above $70, it is only suitable for investors who already track the company deeply and can accept lower future returns.

【Target Holding Period】 If bought at a sufficient discount, it is suitable for 5 to 10 years or longer. Without a discount, long-term holding merely postpones valuation risk; it does not automatically turn into high returns.

【Expected Annualized Return】 Based on the current price of about $101, my rough estimate is: 1% to 3% in the conservative scenario, 4% to 6% in the base scenario, and 7% to 10% in the optimistic scenario. These returns do not come from short-term forecasting, but from a combination of owner earnings growth and normalization toward reasonable valuation. The problem is that the base-case return is not meaningfully above the current risk-free yield.

【Maximum Loss Risk】 If growth remains mediocre over the next two or three years, margin recovery fails, and the market compresses EV/EBITDA or P/FCF multiples, a 30% to 50% drawdown from the current level is not hard to imagine. If acquisition impairments or policy shocks are added, losses could be larger. For this company, the largest permanent capital loss scenario is not "cash flow suddenly goes to zero," but "long-term returns stay below your opportunity cost."

【Tracking Indicators】 Going forward, I would focus on: organic revenue growth; gross margin; GAAP operating margin; operating cash flow from continuing operations; owner earnings; net debt/EBITDA; deferred revenue and software/service mix; accounts receivable turnover; frequency of restructuring and other adjustments; and capital allocation direction, especially buyback prices and discipline on new acquisitions.

【Signals That Trigger Reassessment】 I would immediately reassess if any of the following occur: gross margin stays around 54% or lower for a prolonged period; restructuring expenses remain high for several consecutive years; accounts receivable again grows materially faster than revenue; net debt/EBITDA rises while the company continues large acquisitions; goodwill impairment or major adverse regulatory/reimbursement changes appear.

【Final Recommendation】 Put plainly, Revvity is worth studying, but today it is more worth waiting for. For long-term, balanced, conservative-leaning investors, the key is not deciding whether this company is "good or bad," but deciding "at what price this business becomes attractive enough." In my view, it is past the stage where it can be bought casually, but it has not reached the point where it must be avoided. The most rational action is: keep tracking it, and wait for either the price or the operating results to provide a clearer edge.

Open Questions and Limitations

This report prioritizes Revvity's and peer companies' original annual reports, quarterly reports, and official investor materials. Therefore, it does not provide a sell-side-database-style comprehensive presentation of peers' precise same-day valuation multiples, and instead focuses on Revvity's own true cash flow, capital structure, and intrinsic value framework. In addition, maintenance capital expenditures cannot be directly separated from company disclosures. In owner earnings, I used a conservative treatment by treating all capital expenditures and stock-based compensation as shareholder costs. If more detailed segment capex, software ARR, and organic growth data become available in the future, the valuation range can be narrowed further.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.